Back to results
US 10,520,508 B2Granted
Predictive baseline biomarkers for use of vascular disrupting agents
AssigneeBionomics Limited
InventorsGabriel Kremmidiotis, Annabell Francis Leske
Life of this patent
Estimating the term…
Abstract
The present disclosure relates to the biological markers Ferritin and IL-8 that are predictive for patient response to treatment with a vascular disrupting agent. In particular, the present disclosure relates to biological markers predictive for cancer patient response to treatment with a vascular disrupting agent, as well as methods of treating a cancer patient with a vascular disrupting agent.
Claims10
A method of treating cancer in a patient, the method comprising:
- i) identifying a patient having levels of a first biological marker and a second biological marker prior to being administered a vascular disrupting agent which are greater or less than reference levels of the first and second biological markers, wherein
- the first biological marker is Ferritin and the level of this biological marker in the patient is greater than or equal to the reference level of this biological marker, and the second biological marker is IL-8 and the level of this biological marker in the patient is less than or equal to the reference level of this biological marker, and
- ii) administering the vascular disrupting agent to the patient,
- wherein the vascular disrupting agent is selected from 2-methyl-7-hydroxy-3-(3,4,5-trimethoxybenzoyl)-6-methoxybenzofuran (BNC105) and disodium [6-methoxy-2-methyl-3-(3,4,5-trimethoxybenzoyl)-1-benzofuran-7-yl] phosphate (BNC105P), and
- wherein the patient is a renal cancer patient.
2 more elements
Dependencies are inferred from the claim text.